The third type of Corona vaccine may be soon available in India. Serum Institute of India’s CEO Adar Poonawala said that, Company has applied for trials of Covovax, a vaccine of Novavax. In a tweet he said that Covovax may be launched by June 2021 in Country.
As per the statement shared by Novovax, Covovax has shown the efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom.
The study assessed efficacy during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely. It was conducted in partnership with the UK Government’s Vaccines Taskforce.
Novavax also announced successful results of its Phase 2b study conducted in South Africa.
Stanley C. Erck, President and Chief Executive Officer of Novavax says, it is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants.
Support Ethical Journalism. Support The Dispatch
The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism